PCSK9 and Alzheimer disease: To evaluate whether therapeutic targeting of peripheral PCSK9 would increase Aβ brain clearance in vivo, we i.p. injected FDA-approved monoclonal anti-PCSK9 antibodies repetitively into the AD mouse model 5xFAD to inhibit endogenous PCSK9 activity.